Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma

NCT06124001 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Hepatocellular Carcinoma

Interventions

DRUG: Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
DRUG: camrelizumab for Injection

Sponsor

CNBG-Virogin Biotech (Shanghai) Ltd.